P300 is elevated in systemic sclerosis and its expression is positively regulated by TGF-β: Epigenetic feed-forward amplification of fibrosis

Journal of Investigative Dermatology

Volumn 133, Issue 5, 2013, Pages 1302-1310

  Ghosh, Asish K ^a   Bhattacharyya, Swati ^a   Lafyatis, Robert ^b   Farina, Giuseppina ^b   Yu, Jianxiu ^c   Thimmapaya, Bayar ^a   Wei, Jun ^a   Varga, John ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN TYPE 1; E1A ASSOCIATED P300 PROTEIN; EARLY GROWTH RESPONSE FACTOR 1; SMAD PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; FIBROGENESIS; HISTONE ACETYLATION; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SKIN BIOPSY; SKIN FIBROBLAST; SKIN FIBROSIS; SYSTEMIC SCLEROSIS;

EID: 84876684186     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2012.479     Document Type: Article

References (35)

1. Baluchamy S, Rajabi HN, Thimmapaya R et al. (2003) Repression of c-Myc and inhibition of G1 exit in cells conditionally overexpressing p300 that is not dependent on its histone acetyltransferase activity. Proc Natl Acad Sci USA 100:9524-9
2. Bhattacharyya S, Ghosh AK, Pannu J et al. (2005) Fibroblast expression of the coactivator p300 governs the intensity of profibrotic response to transforming growth factor beta. Arthritis Rheum 52:1248-58
3. Bhattacharyya S, Sargent JL, Du P et al. (2011) Egr-1 induces a profibrotic injury/repair gene program associated with systemic sclerosis. PloS One 6:e23082
4. Chen SJ, Ning H, Ishida W et al. (2006) The early-immediate gene EGR-1 is induced by transforming growth factor-beta and mediates stimulation of collagen gene expression. J Biol Chem 281:21183-97
5. Chen SJ, Yuan W, Mori Y et al. (1999) Stimulation of type I collagen transcription in human skin fibroblasts by TGF-beta: involvement of Smad 3. J Invest Dermatol 112:49-57
6. Czuwara-Ladykowska J, Sementchenko VI, Watson DK et al. (2002) Ets1 is an effector of the transforming growth factor beta (TGF-beta ) signaling pathway and an antagonist of the profibrotic effects of TGF-beta. J Biol Chem 277:20399-408
7. Eliseeva ED, Valkov V, Jung M et al. (2007) Characterization of novel inhibitors of histone acetyltransferases. Mol Cancer Ther 6:2391-8
8. Ghosh AK (2002) Factors involved in the regulation of type I collagen gene expression: implication in fibrosis. Exp Biol Med (Maywood) 227:301-14
9. Ghosh AK, Bhattacharyya S, Varga J (2004) The tumor suppressor p53 abrogates Smad-dependent collagen gene induction in mesenchymal cells. J Biol Chem 279:47455-63
10. Ghosh AK, Bhattacharyya S, Wei J et al. (2009) Peroxisome proliferator-activated receptor-gamma abrogates Smad-dependent collagen stimulation by targeting the p300 transcriptional coactivator. FASEB J 23: 2968-77
11. Ghosh AK, Mori Y, Dowling E et al. (2007) Trichostatin A blocks TGF-beta-induced collagen gene expression in skin fibroblasts: involvement of Sp1. Biochem Biophys Res Commun 354:420-6
12. Ghosh AK, Varga J (2007) The transcriptional coactivator and acetyltransferase p300 in fibroblast biology and fibrosis. J Cell Physiol 213:663-71
13. Ghosh AK, Yuan W, Mori Y et al. (2001) Antagonistic regulation of type I collagen gene expression by interferon-gamma and transforming growth factor-beta. Integration at the level of p300/CBP transcriptional coactiva-tors. J Biol Chem 276:11041-8
14. Ghosh AK, Yuan W, Mori Y et al. (2000) Smad-dependent stimulation of type I collagen gene expression in human skin fibroblasts by TGF-beta involves functional cooperation with p300/CBP transcriptional coactivators. Onco-gene 19:3546-55
15. Giles RH, Peters DJ, Breuning MH (1998) Conjunction dysfunction: CBP/p300 in human disease. Trends Genet 14:178-83
16. Goodman RH, Smolik S (2000) CBP/p300 in cell growth, transformation, and development. Genes Dev 14:1553-77
17. Ihn H, Yamane K, Asano Y et al. (2006) Constitutively phosphorylated Smad3 interacts with Sp1 and p300 in scleroderma fibroblasts. Rheumatology (Oxford) 45:157-65
18. Iyer NG, Ozdag H, Caldas C (2004) p300/CBP and cancer. Oncogene 23:4225-31
19. Janknecht R (2002) The versatile functions of the transcriptional coactivators p300 and CBP and their roles in disease. Histol Histopathol 17:657-68
20. Kaimori A, Potter JJ, Choti M et al. (2010) Histone deacetylase inhibition suppresses the transforming growth factor beta1-induced epithelial-to-mesenchymal transition in hepatocytes. Hepatology 52:1033-45
21. Kassimatis TI, Giannopoulou I, Koumoundourou D et al. (2006) Immunohis-tochemical evaluation of phosphorylated SMAD2/SMAD3 and the co-activator P300 in human glomerulonephritis: correlation with renal injury. J Cell Mol Med 10:908-21
22. Kraus WL, Kadonaga JT (1998) p300 and estrogen receptor cooperatively activate transcription via differential enhancement of initiation and reinitiation. Genes Dev 12:331-42
23. Li M, Luo RZ, Chen JW et al. (2011a) High expression of transcriptional coactivator p300 correlates with aggressive features and poor prognosis of hepatocellular carcinoma. J Transl Med 9:5
24. Li Y, Yang HX, Luo RZ et al. (2011b) High expression of p300 has an unfavorable impact on survival in resectable esophageal squamous cell carcinoma. Ann Thorac Surg 91:1531-8
25. Lim JY, Oh MA, Kim WH et al. (2012) AMP-activated protein kinase inhibits TGF-beta-induced fibrogenic responses of hepatic stellate cells by targeting transcriptional coactivator p300. J Cell Physiol 227:1081-9
26. Liu T, Dhanasekaran SM, Jin H et al. (2004) FIZZ1 stimulation of myofibroblast differentiation. Am J Pathol 164:1315-26
27. Petrij F, Giles RH, Dauwerse HG et al. (1995) Rubinstein-Taybi syndrome caused by mutations in the transcriptional co-activator CBP. Nature 376:348-51
28. Roelfsema JH, White SJ, Ariyurek Y et al. (2005) Genetic heterogeneity in Rubinstein-Taybi syndrome: mutations in both the CBP and EP300 genes cause disease. Am J Hum Genet 76:572-80
29. Saha RN, Pahan K (2006) HATs and HDACs in neurodegeneration: a tale of disconcerted acetylation homeostasis. Cell Death Differ 13:539-50
30. Santer FR, Hoschele PP, Oh SJ et al. (2011) Inhibition of the acetyltransferases p300 and CBP reveals a targetable function for p300 in the survival and invasion pathways of prostate cancer cell lines. Mol Cancer Ther 10:1644-55
31. Varga J (2002) Scleroderma and Smads: dysfunctional Smad family dynamics culminating in fibrosis. Arthritis Rheum 46:1703-13
32. Vo N, Goodman RH (2001) CREB-binding protein and p300 in transcriptional regulation. J Biol Chem 276:13505-8
33. Wu M, Melichian DS, Chang E et al. (2009) Rosiglitazone abrogates bleomycin-induced scleroderma and blocks profibrotic responses through peroxisome proliferator-activated receptor-gamma. Am J Pathol 174:519-33
34. Yokomizo C, Yamaguchi K, Itoh Y et al. (2011) High expression of p300 in HCC predicts shortened overall survival in association with enhanced epithelial mesenchymal transition of HCC cells. Cancer Lett 310:140-7
35. Yu J, de Belle I, Liang H et al. (2004) Coactivating factors p300 and CBP are transcriptionally crossregulated by Egr1 in prostate cells, leading to divergent responses. Mol Cell 15:83-94